Congratulations to Fujian Haixi Pharmaceutical Co., Ltd. (2637.HK) on its Successful Listing

Congratulations to Fujian Haixi Pharmaceutical Co., Ltd. (2637.HK) on its successful Listing on the Mainboard of HKSE on 20 Oct 2025

Fujian Haixi Pharmaceutical Co., Ltd. (“Haixi Pharmaceutical”) is a commercial-stage pharmaceutical company that integrates R&D, production and sales capacities, with a pipeline of innovative drug candidates. Haixi Pharmaceutical has a diversified product portfolio and pipeline in the largest and fastest growing therapeutic areas in China. Haixi Pharmaceutical’s commercialized product portfolio primarily consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases.

With regard to this listing application, AVISTA Group is honored to be engaged in providing ESG advisory services, valuation services in relation to the financial asset and investment property.

Congratulations again Fujian Haixi Pharmaceutical Co., Ltd. (2637.HK) on its successful listing. The issue price of the shares is HKD86.4 per share, and the amount of funds raised is 993.6 million HKD.